Translational Development Acquisition Corp. (TDACW) |
| 1.9 -0.1 (-5%) 07-13 15:58 |
| Open: | 0.325 |
| High: | 2.38 |
| Low: | 0.325 |
| Volume: | 5,176 |
| Market Cap: | 250(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Global Market |
| Industry: | Shell Companies |
| Sector: | Financial Services |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 10.80 |
| Resistance 1: | 10.75 |
| Pivot price: | 10.71 |
| Support 1: | 10.67 |
| Support 2: | 8.88 |
| 52w High: | 2.38 |
| 52w Low: | 0.325 |
Translational Development Acquisition Corp., established in 2022 and headquartered in New York, New York, currently possesses no significant business operations. Its primary objective is to finalize a strategic business combination, which could involve a merger, share exchange, asset acquisition, or reorganization, with one or more other entities.
Financials
| EPS | 0.280 |
| Book Value | -0.310 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -0.3 |
| Return on Equity (ttm) | 0.0 |
Company news
Tue, 23 Jun 2026
Form 8K Translational Development Unit For: 23 June By Investing.com - Investing.com Canada
Tue, 23 Jun 2026
Translational Development (TDAC) files redemption update on ProLogium deal (TDAC) - Stock Titan
Thu, 18 Jun 2026
TDAC (NASDAQ: TDAC) wins shareholder approval to extend SPAC deal deadline to 2027 - Stock Titan
Thu, 11 Jun 2026
PZZA Q1 2026 Earnings: EPS Falls Short of Estimates Amid Operational Headwinds - Analyst Earnings Estimate - dars.gov.et
Thu, 11 Jun 2026
TDACW Warrants Retreat 3.48%, Testing Key Support Levels - Modified Schiff - dars.gov.et
Wed, 27 May 2026
ProLogium to list on Nasdaq via TDAC merger at $3.8B valuation - Seeking Alpha
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
